@newtonbuilt's testosterone therapy claims, fact-checked
Quick answer
The video captures an apparent inadvertent intravascular event during self-injection of what is presumed to be an oil-based testosterone preparation, likely cypionate or enanthate. Pulmonary oil microembolism (POME) is a documented adverse event in this context, presenting with respiratory symptoms within minutes of injection. Anyone self-administering oil-based testosterone who experiences immediate coughing, chest tightness, or lightheadedness post-injection should contact their prescribing provider or seek urgent care.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @newtonbuilt actually say?
On camera, mid-injection, @newtonbuilt told his 2.8 million viewers he had just hit a vein, then immediately said hitting a vein is "super unlikely." That's the entire claim, compressed into a moment of visible panic. It's actually a two-part statement: something bad just happened, and also that thing almost never happens. Both halves deserve scrutiny.
To his credit, he didn't catastrophize or give dangerous follow-up advice. He didn't tell people to push through a vein strike, change the dose, or do anything reckless. He just reacted, labeled it rare, and moved on. That restraint matters in a 2.8 million view context.
Does the science back this up?
Yes, mostly. Inadvertent intravascular injection during intramuscular (IM) injection is genuinely uncommon, and the data supports calling it unlikely. The mechanism that makes it rare is anatomical: the gluteal, vastus lateralis, and deltoid sites used for testosterone injections sit in muscular tissue with relatively small-caliber vessels, not major veins.
A 2015 systematic review by Nicoll and Hesby in the Journal of Infusion Nursing found that aspiration before IM injection, historically used to check for vein entry, was not evidence-based and has largely been abandoned in clinical guidelines, precisely because vascular placement at standard IM sites is uncommon enough that the practice added no meaningful safety benefit. The World Health Organization formally recommended against routine aspiration for most IM sites in 2015.
That said, "super unlikely" doesn't mean impossible, as @newtonbuilt just demonstrated live. Estimated rates of inadvertent intravascular injection at IM sites range from less than 1% to around 2% depending on technique, needle length, and injection site.
What did they get wrong (or right)?
He got the core fact right: hitting a vein during a standard intramuscular testosterone injection is a low-probability event. The literature supports this. Where the video falls short is what it doesn't say, which matters a lot given the audience size.
What actually happens when you do hit a vein during a testosterone injection? The risk isn't bleeding out. The real concern is oil embolism. Testosterone cypionate and enanthate are suspended in carrier oils, typically cottonseed or sesame. If that oil gets pushed into a vein, it can travel to the lungs. Case reports of pulmonary oil microembolism (POME) from intravascular testosterone injection exist in the literature. Lunning et al. (2014, JAMA Internal Medicine) documented POME cases presenting with coughing, chest tightness, and dizziness within minutes of injection.
The tell-tale sign he didn't mention: if you aspirate blood into the syringe, or if you get a sudden cough, chest pain, or feel faint immediately after injecting, those are red flags that warrant stopping and seeking care. A passing "oh fuck" doesn't cover that ground.
What should you actually know?
If you inject testosterone at home, here is what the evidence actually recommends. First, hitting a vein during a proper IM injection is uncommon, under 2% in most estimates, and @newtonbuilt is right about that. Second, the consequences when it does happen are not trivial. Oil embolism from oil-based testosterone injections is a documented, real adverse event, not a scare tactic.
Current clinical guidance from the Endocrine Society (2018 clinical practice guidelines) recommends standard IM injection technique at validated sites. Many clinicians have moved to subcutaneous injection for testosterone, which carries essentially zero vascular placement risk and has shown comparable pharmacokinetics for depot formulations (Spratt et al., 2021, Journal of Clinical Endocrinology and Metabolism).
Signs of possible pulmonary oil microembolism include immediate or near-immediate coughing, chest discomfort, shortness of breath, or feeling faint after injection. If those occur, stop the injection immediately and contact a medical provider. This is not a "walk it off" situation. If you are self-injecting testosterone without clinical supervision, this video is a good reminder that a telehealth provider relationship is not optional, it is a safety layer.
The bottom line
@newtonbuilt's offhand claim that hitting a vein is "super unlikely" during a testosterone injection is accurate by the numbers. The problem is what he didn't say: when it does happen with an oil-based hormone preparation, there's a documented path to pulmonary complications. A 2.8 million view moment of panic deserved a 30-second explanation. It didn't get one.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @newtonbuilt's testosterone therapy claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@newtonbuilt's testosterone therapy claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The video captures an apparent inadvertent intravascular event during self-injection of what is presumed to be an oil-based testosterone preparation, likely cypionate or enanthate.
FormBlends verdict
The video captures an apparent inadvertent intravascular event during self-injection of what is presumed to be an oil-based testosterone preparation, likely cypionate or enanthate. Pulmonary oil microembolism (POME) is a documented adverse event in this context, presenting with respiratory symptoms within minutes of injection. Anyone self-administering oil-based testosterone who experiences immediate coughing, chest tightness, or lightheadedness post-injection should contact their prescribing provider or seek urgent care.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video captures an apparent inadvertent intravascular event during self-injection of what is presumed to be an oil-based testosterone preparation, likely cypionate or enanthate. Pulmonary oil microembolism (POME) is a documented adverse event in this context, presenting with respiratory symptoms within minutes of injection. Anyone self-administering oil-based testosterone who experiences immediate coughing, chest tightness, or lightheadedness post-injection should contact their prescribing provider or seek urgent care.
- Inadvertent intravascular injection during IM testosterone administration occurs in under 2% of injections at standard sites, according to clinical injection technique literature.
- The WHO removed routine pre-injection aspiration from its 2015 guidelines because vascular placement at typical IM sites (gluteal, vastus lateralis, deltoid) is uncommon enough that aspiration provided no meaningful safety benefit.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Inadvertent intravascular injection during IM testosterone administration occurs in under 2% of injections at standard sites, according to clinical injection technique literature.
- The WHO removed routine pre-injection aspiration from its 2015 guidelines because vascular placement at typical IM sites (gluteal, vastus lateralis, deltoid) is uncommon enough that aspiration provided no meaningful safety benefit.
- Oil-based testosterone formulations (cypionate, enanthate) carry a specific risk called pulmonary oil microembolism (POME) if injected intravascularly. Lunning et al. (2014, JAMA Internal Medicine) documented real cases with respiratory symptoms.
- Warning signs of POME include immediate coughing, chest tightness, shortness of breath, or near-fainting within minutes of injection. These require prompt medical contact, not observation.
- Subcutaneous injection of testosterone has been studied as an alternative with comparable pharmacokinetics and near-zero vascular placement risk. Spratt et al. (2021, Journal of Clinical Endocrinology and Metabolism) found similar absorption profiles.
- Self-injecting testosterone without clinical oversight removes the safety layer that catches and responds to adverse events like this one. A telehealth or in-person prescriber relationship is a documented harm-reduction factor, not a bureaucratic obstacle.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
newtonbuilt · TikTok creator
2.8M views on this video
@newtonbuilt's testosterone therapy claims, fact-checked
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by newtonbuilt, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.